Madrigal Pharmaceuticals, Inc. announced that Bill Sibold has succeeded Paul Friedman, M.D., as Chief Executive Officer (CEO) and joined Madrigal?s Board of Directors. Dr. Friedman, who has served as Madrigal?s CEO since 2016, will continue to serve on the Board of Directors. From 2017 until joining Madrigal, Mr. Sibold served as Executive Vice President, Specialty Care of Sanofi and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas (Immunology, Oncology, Rare Disease, Rare Blood Disorders, and Neurology) and served as a member of the Sanofi Executive Committee.

Sanofi Specialty Care achieved sustained double-digit growth during his tenure, becoming the company's larger Global Business Unit. This included leading the launch of Dupixent, a first-in-class therapy which has grown into an medicine. From 2015 to 2017, he served as Senior Vice President (SVP), Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme.

Mr. Sibold first joined Sanofi Genzyme in 2011 as Global Franchise Head Multiple Sclerosis. Previously, Mr. Sibold served as Chief Commercial Officer of Avanir Pharmaceuticals, President and CEO of Lycera Corp., and SVP U.S. Commercial for Biogen. Mr. Sibold holds a B.A. Degree in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from Harvard Business School.